UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 28, 2019

DELMAR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)

Nevada	001-37823	99-0360497
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Suite 720-999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (604) 629-5989

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	DMPI	The Nasdaq Capital Market

Item 7.01. Regulation FD Disclosure.

On August 28, 2019, DelMar Pharmaceuticals, Inc. (the "Company") used the slides attached hereto as Exhibit 99.1 in connection with management presentations to describe its business.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

Exhibit No.	Description
99.1	Investor Presentation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELMAR PHARMACEUTICALS, INC.

Date: August 28, 2019

By: /s/ Scott Praill
Scott Praill
Chief Financial Officer

Exhibit 99.1

DelMar PHARMACEUTICALS

Breakthrough Cancer Therapeutics

VAL-083: Validated DNA-targeting Agent for Multiple Drug Resistant Solid Tumor Indications

August 2019

NASDAQ: DMPI

Forward Looking Statements

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein or made in the course of the presentation are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including its current reports on Form 8-K's, Form 10-Q's and most recent Form 10-K. DelMar Pharmaceuticals does not undertake to update these forward-looking statements made.

Highly De-Risked Late-Stage Phase 2 Programs

- Demonstrated **Efficacy**
  - Validated biological and tumor effecting activity
  - Biomarker enriched patient population
- Well Characterized **Safety** Profile
  - Large historical safety database of over 1,000 patients
- Mature **Manufacturing** Status
  - CMC advanced to Phase 3 / commercial stage
- Efficient **Capital** Management
  - Low quarterly burn
  - Funded through full enrollment for all three Phase 2 study arms
- Executing **Clinical Development** through expert centers
  - Phase 2 studies being conducted by M.D. Anderson Cancer Center (MDACC) and Sun Yat-sen University Cancer Center (SYSUCC)
  - Supported by world class Scientific Advisory Board with deep GBM expertise

Corporate and Product Overview

- VAL-083
  - First-in-class, small molecule, DNA-targeting agent
  - Established and unique mechanism of action
  - Proven to cross the blood-brain barrier
- Lead indication
  - Biomarker-driven, MGMT-unmethylated glioblastoma multiforme (GBM)
  - Three distinct GBM patient populations in Phase 2 studies
- 505(b)(2) path allows use of prior toxicology and clinical data from National Cancer Institute (exclusively authorized to DelMar[-1]) and other studies to support FDA filings
- Fast Track Designation and Orphan Drug Designations (US and EU)

1. Letter of Authorization November 3, 2010

Validated Biological Activity of VAL-083

- Previous work at National Cancer Institute (NCI) demonstrated efficacy of compound
  - Randomized trial in 42 patients:
    - Radiation only patients mOS of 35 weeks
    - Radiation and VAL-083 mOS of 67 weeks [-1]
- VAL-083 Effectively Crosses Blood-Brain Barrier
  - Established in previous NCI work [-2]
  - Further demonstrated through PK data from ongoing Phase 2 clinical trial at SYSUCC [-3]
- Myelosuppression is consistent with other successful approved chemotherapy treatments
- VAL-083's unique mechanism of action creates inter-strand DNA cross-links at the N7 position of guanine, resulting in double-strand DNA breaks and cancer cell death via apoptosis [-4]

1. Eagan 1979 JAMA
2. Eckhardt 1977 Cancer Treat Rep
3. Chen AACR Poster 2019
4. Fouse 2014 Neuro Oncol

Biomarker Enriched Patient Population



1. Hegi 2005 N Eng J Med

Biomarker Enriched Patient Population

- Evaluating MGMT promoter methylation has become standard practice in GBM diagnosis, treatment, and outcomes
- September 2017 NCCN guidelines highlight limited effectiveness of temozolomide (TMZ) for patients with MGMT-unmethylated tumors [-1]
  - TMZ monotherapy [for patients with KPS<60] in only recommended if tumor is MGMT-methylated
  - Clinical benefit from TMZ is likely to be lower in patients whose tumors are MGMT-unmethylated
- MGMT testing is a commercially available diagnostic

LabCorp ARUP LABORATORIES HistoGeneX Allscripts

1. NCCN Guidelines Version 1.2017

Biomarker Enriched Patient Population

U251 MGMT-Methylated GBM



T98G MGMT-Unmethylated GBM



VAL-083 is Equipotent Independent of MGMT Promoter Methylation Status [1]

1. Hu 2012 AACR poster

Biomarker Enriched Patient Population

"Treating patients with glioblastoma with unmethylated MGMT promoter is particularly challenging. These tumors are inherently resistant to the temozolomide, which alkylates DNA at the O-6 position of methylguanine, and is readily repaired by MGMT. VAL-083 has been shown to be safe and may provide a valuable treatment option for these patients" -1

"We agree that we desperately need something better to offer our patients and we feel that VAL-083 has some promise and potential" -2

1. Dr. Barbara O'Brien, Assistant Professor, Department of Neuro-Oncology at MD Anderson Cancer Center
   Principal Investigator on DelMar rGBM and Adjuvant arm trial
2. Dr. David Reardon, Clinical Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute
   Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center
   Members, DelMar Scientific Advisory Board

Well Characterized Safety Profile

- DelMar's GBM program builds on previous work from the National Cancer Institute
  - ~40 Phase 1 and Phase 2 clinical trials in multiple indications as well as significant preclinical work
  - More than 1,000 patient historical safety database
- Safety database augmented by completed and ongoing DelMar clinical trials with addition of over 100 patients to date
- Consistent with prior NCI data, myelosuppression has been the most common adverse event (AE); AEs have generally resolved spontaneously

Advanced Manufacturing Status

- VAL-083 Drug Substance (DS) manufactured by STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTech company
  - STA focused on late stage and commercial DS manufacturing
  - Engineering and GMP lots manufactured; strong stability results
- VAL-083 Drug Product (DP) manufactured by Chemi Pharma (subsidiary of Italfarmaco)
  - Chemi Pharma is focused on late stage and commercial DP manufacturing
  - Robust process built on lyophilization temperature
  - Engineering and GMP lots manufactured; strong purity and stability results
  - Additional IP generated on process and methods

Efficient Capital Management

- Only $38.8M in shareholder capital spent to establish multiple clinical programs (through March 31, 2019)
- Low quarterly burn
  - Efficient internal operations and low fixed costs
  - Exceptional value from clinical partners at MDACC and SYSUCC
- Program funded through patient enrollment for all three Phase 2 study arms

VAL-083 Clinical Development Program



1. Hegi 2005 N Eng J Med

VAL-083 Clinical Development Program



VAL-083 Clinical Development Program



VAL-083 Recurrent Study Arm

- Validate VAL-083 in recurrent, Avastin-naïve MGMT-unmethylated GBM patients post TMZ failure
  - Primary endpoint is Median Overall Survival compared to historical control of Lomustine at 7.2 months
  - Conducted at MDACC (NCT02717962)
- 56 of 83 planned **recurrent** patients have been enrolled [-1]
- 47 patients have received assessment at end of cycle 2 [-2]
  - 13/47 (28%) patients have been assessed as Stable Disease
- Consistent with prior studies, myelosuppression is the most common adverse event

1. Data cut-off 24-Jul-2019
2. Data cut-off 5-May-2019
   Assessment based on Investigator's clinical and radiologic assessment according to RANO criteria

VAL-083 Adjuvant Study Arm

- Validate VAL-083 in adjuvant GBM MGMT-unmethylated patients post radiation
  - Primary endpoint is Progression Free Survival compared to historical control of TMZ at 6.9 months
  - Conducted at MDACC (NCT02717962)
- First of 24 planned **adjuvant** patients has been enrolled [-1]

1. Data cut-off 24-Jul-2019

VAL-083 Newly-Diagnosed Study Arm

- Validate VAL-083 in newly-diagnosed MGMT-unmethylated GBM patients
  - Primary endpoint is Progression Free Survival compared to historical control of TMZ at 6.9 months
  - Conducted at SYSUCC (NCT03050736)
- 20 of 30 planned **newly-diagnosed** patients have been enrolled [-1]
- 17 patients have received at least one assessment [-2]
  - 9/17 (53%) assessed as Complete Response
  - 7/17 (41%) assessed as Stable Disease
  - One patient assessed as Disease Progression (6%); two patients not on study long enough to be assessed; one patient died before first assessment time point
  - **"For a tumor such as GBM, which is intrinsically infiltrative and destructive in the brain, stabilization of disease is an important achievement."** [-3]
  - Consistent with prior studies, myelosuppression is the most common adverse event

1. Data cut-off 1-Aug-2019
2. Best Overall Response based on Investigator's clinical and radiologic assessment according to RANO criteria
3. Dr. David Reardon, Clinical Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute

VAL-083 Initial Market Opportunity

- GBM is the most common adult brain tumor with annual incidence ~29,000 new cases in US and EU [-1]
- >17,000 Newly-diagnosed and adjuvant MGMT-unmethylated patients annually [-2]
- >12,000 Recurrent MGMT-unmethylated patients annually [-3]

1. CBTRUS report 2017
2. Hegi 2005, N Eng J Med
3. Brandes 2009, J Clin Onc

Scientific Advisory Board

- Dr. Napoleone Ferrara
  - World renowned scientist and Distinguished Professor of Pathology and a Distinguished Adjunct Professor of Ophthalmology and Pharmacology at the **University of California, San Diego**
- Dr. John de Groot
  - Chairman, ad interim of the Department of Neuro-Oncology at **MD Anderson Cancer Center**
- Dr. David Reardon
  - Clinical Director of the Center for Neuro-Oncology at the **Dana-Farber Cancer Institute and Professor of Medicine at the Harvard Medical School**
- Dr. Timothy Cloughesy
  - Professor of neurology at **David Geffen School of Medicine at the UCLA** and member of **UCLA Brain Research Institute and Jonsson Comprehensive Cancer Center**
- Dr. Nicholas Butowski
  - Neuro-oncologist practicing at **UCSF Medical Center and Director of translational research in neuro-oncology and a researcher at the Brain Tumor Center**

Corporate and Product Summary

- Highly De-Risked Late Phase 2 Program
  - Demonstrated **Efficacy**
  - Well Characterized **Safety** Profile
  - Mature **Manufacturing** Status
  - Efficient **Capital** Management
  - Executing **Clinical Development** through expert and highly regarded centers
- Opportunities in biomarker-enriched patient population across all GBM disease stages
  - **Newly-diagnosed** patients (1st line)
  - **Adjuvant** patients (Post initial cycle with radiation therapy)
  - **Recurrent** patients (2nd line)
- Fast Track and Orphan Drug Designations

DelMar PHARMACEUTICALS

Breakthrough Cancer Therapeutics

Corporate Headquarters

Suite 720-999 W. Broadway
Vancouver BC V5Z 1K5
Canada

Clinical Operations

3475 Edison Way, Suite R
Menlo Park, CA 94025
USA

NASDAQ: DMPI